Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery
Chuanke Zhao,Zhuona Rong,Jin Ding,Lixin Wang,Bing Wang,Lei Ding,Lin Meng,Xiangxi Meng,Feng Wang,Zhi Yang,Chengchao Shou,Hua Zhu
DOI: https://doi.org/10.1021/acs.molpharmaceut.1c00947
2022-03-28
Molecular Pharmaceutics
Abstract:Claudin 18.2 (CLDN18.2) is a new potential target for cancer therapy, especially for advanced gastric cancer (AGC). A molecular targeting probe is of importance for patient stratification and therapeutic guidance. Here, we explored an antibody-dependent molecular imaging strategy for specific detection and surgery guidance based on a CLDN18.2-specific antibody, 5C9. Two imaging probes, 124I-5C9 and Cy5.5-5C9, were synthesized. The specificity to CLDN18.2 being evidenced in the cellular experiments with control, the diagnostic utility was assessed by immunopositron emission tomography (immuno-PET) and fluorescence imaging using xenograft models. A near-infrared fluorescent II imaging probe FD1080-5C9 was designed to facilitate the comprehensive surgical removal of lesions. 124I-5C9 immuno-PET imaging clearly delineated subcutaneous CLDN18.2-positive tumors, with a peak uptake (maximum standardized uptake value; SUVmax) of 2.25 ± 0.30, whereas the highest values for the 124I-IgG and blocking groups were 0.70 ± 0.13 and 0.66 ± 0.12, respectively. Cy5.5-5C9 fluorescence imaging showed similar results. As proof of the diagnosis and guided surgery (DGS) concept, 124I-5C9 and FD1080-5C9 were simultaneously administered in orthotopic CLDN18.2-positive tumor models, facilitating the comprehensive resection of tumor tissue. Combined, 124I-5C9 and FD1080-5C9 are both promising DGS tools: the former reveals CLDN18.2 in lesions as a PET probe, and the latter can guide surgery. These results provide a utility molecular imaging strategy for specific detection and surgery guidance based on a CLDN18.2-specific antibody both in AGC and other cancers.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.1c00947.NIR-II guided surgery (MP4)Experimental details on reagents, cell culture, xenograft and orthotopic models, generation of an anti-CLDN18.2-specific antibody, and statistical analysis; Figure S1 showing a comparison of stability and physiological activity of labeled and unlabeled 5C9; Figure S2 showing radio-HPLC of 124I-5C9 in PBS after 0, 24, 48, 96 h and UV curve of 5C9 at 280 nm; Figure S3 showing biodistribution study of 124I-5C9; Figure S4 showing SUVmax trend of ROIs (heart, liver, spleen, lung, kidney, tumor) in images of four groups from 4 to 240 h (PDF)This article has not yet been cited by other publications.
pharmacology & pharmacy,medicine, research & experimental